Our Mission
The ACC Nevada Chapter is dedicated to advancing the field of cardiovascular care through innovation, advocacy, and professional development, ensuring that Nevada’s clinicians are equipped to meet the evolving health challenges of our state.
|
ACC Live Courses For a listing of all ACC Live Courses please visit: https://www.acc.org/education-and-meetings/meetings |
Please join our cardiology colleagues at the ACC Annual Meeting, a premier gathering of cardiovascular professionals from around the world. This dynamic conference brings together leading physicians, researchers, healthcare innovators, and industry experts to explore the latest advances in cardiovascular medicine. Attendees will experience cutting-edge clinical education, groundbreaking research presentations, interactive learning sessions, and exceptional networking opportunities focused on improving patient care and advancing the future of heart health.
Latest in Cardiology from ACC.org
- MERCURI-2: Dapagliflozin Before Cardiac Surgery Lowers Postoperative AKI RiskStarting dapagliflozin one day before elective cardiac surgery reduced the incidence of postoperative acute kidney injury (AKI) during the first seven days after surgery, according to results from the double-blind, placebo-controlled MERCURI-2 trial published July 30 in JAMA.
- FFR in Focus: New Insights on Angiography-Derived Assessment and FFR-NHPR DiscordanceTwo studies recently published in JACC: Cardiovascular Interventions provide fresh insights into coronary physiology, suggesting that angiography-derived fractional flow reserve (FFR) may be a practical alternative to wire-based FFR, while highlighting the prognostic significance of definite discordance between FFR and nonhyperemic pressure ratios (NHPR).
- Central Adiposity as Predictor of CV Outcomes | JACC Special Issue on ObesityWaist circumference (WC) and waist-to-hip ratio (WHR) provide additional diagnostic and prognostic value compared with conventional BMI categories alone, which may misclassify cardiovascular disease risk, according to results from the Cross-Cohort Collaboration (CCC) Obesity Working Group published Aug. 11 in JACC.
- ACCEL Lite: Evolocumab In Patients Without Significant Atherosclerosis: Results From VESALIUS-CVIn this interview, Nanette Kass Wenger MD, MACC and Nicholas Marston, MD discuss the VESALIUS-CV Trial.
- ICECAP: Increasing Duration of Therapeutic Hypothermia After OHCAIncreasing cooling duration in comatose survivors of out-of-hospital cardiac arrest (OHCA) being treated with therapeutic hypothermia did not improve neurological outcomes, according to findings from the multicenter, randomized ICECAP trial published in JAMA.